Ipragliflozin 是一种口服有效的，选择性的SGLT2抑制剂，对人 SGLT2 和 SGLT1，大鼠 SGLT2 和 SGLT1，小鼠 SGLT2 和 SGLT1 的IC50分别为 7.38 和 1876 nM，6.73 和 1166 nM，5.64 和 1380 nM。Ipragliflozin具有抗糖尿病活性。

Ipragliflozin is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2.

Inhibition of TNF-α synthesis: TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA. The concentration of Pomalidomide that inhibits TNF- production by 50% (IC50) is calculated by nonlinear regression analysis. The human whole blood TNF- inhibition assay is run in a similar fashion to the PBMC assay except that heparinized fresh human whole blood is plated directly into microtiter plates.

761423-87-4

C21H21FO5S

404.45

ASP1941;伊格列净

DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years